Off goes ARTL. The stock jumped today. A closer look at the stock:

Artelo Biosciences Inc (ARTL) is trading 37% higher at $5.96 today. The stock is outpacing peers in an otherwise somewhat glum opening for the Health Care sector. The promising biotech company recently reported earnings, but the more likely cause for the move in share prices is the recent publication of of data showing the promise of its FABP inhibitor in helping to treat anxiety-related disorders.

Artelo Biosciences Inc has been trading between a 52-week high of $19.8 and a 52-week low of $3.61 and is trading near the bottom of that range. The stock has a market cap of $244 Million.

Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation.